Patient-reported Outcomes
|
|
- Edmund Hill
- 5 years ago
- Views:
Transcription
1 3 Patient-reported Outcomes Ingela Wiklund Key points Many gastrointestinal diseases are symptomdriven, so the patient s perspective is particularly important in this area. Patient-reported outcomes (PROs) provide essential information that objective measures and clinician assessment may fail to capture. PROs can be measured in a scientific, reliable, and valid manner. Generic, disease-specific and treatmentspecific PRO instruments exist. PRO instruments are valuable for use in clinical trials, to measure treatment outcomes, and also in clinical practice, to describe the burden of illness and to facilitate diagnosis and patient management. Introduction The medical community has traditionally preferred to use objective measures to confirm the presence of disease or to monitor treatment response. For example, these could be a positive test for a disease-causing microorganism, such as Helicobacter pylori, or the results of an endoscopy showing reflux esophagitis. However, many gastrointestinal (GI) diseases have a high symptom burden but little objective evidence for disease or poor correlation with tests for abnormality. Furthermore, because endoscopic and colonoscopic examinations are not generally performed in primary care, the GI tract is largely inaccessible to further investigation in this setting. Primary care physicians are therefore required to rely on the patient s subjective report. Symptoms that are only felt by the patient, such as heartburn or abdominal pain, represent the most common self-reported outcome. The classification of medical outcomes into biologic, clinicianreported, caregiver-reported, and patient-reported is shown in Fig Despite their common use, objective measures do have limitations. The interpretation of objective markers of disease activity, such as endoscopic findings, may differ between clinicians (often referred to as poor inter-rater reliability) [1]. Also, improvements in clinical measures may not correspond to improvements in how a patient feels or is able to function. Some aspectsofdisease,suchaspainintensityandrelief, are known only to the patient. In the absence of objective measures, a physician relies on information from the patient in order to make a diagnosis or to assess whether a treatment is successful. There is therefore a real need to help patients describe their own symptoms in a consistent, standardized way. One way to do this is to use patientreported outcome (PRO) measures. The US Food and Drug Administration has recently put together draft guidance on the use of PRO measures in clinical GI Epidemiology: Diseases and Clinical Methodology, Second Edition. Edited by Nicholas J. Talley et al. C 2014 John Wiley & Sons, Ltd, with the exception of original artwork which is C Mayo Foundation for Medical Education and Research. Published 2014 by John Wiley & Sons, Ltd. Companion website: 16
2 PATIENT-REPORTED OUTCOMES Biological Patient-reported Frequency and severity of GI symptoms Sleep problems Health perception Well-being Treatment satisfaction Caregiver-reported Global impression Functional status Caregiver burden Clinician-reported Global impression Signs Los Angeles classification (esophagitis) Forrest classification (peptic ulcers) Free haemoglobin Bilirubin Esophageal 24 h ph-metry Scintigraphy Histopathology Bacterial culture Figure 3.1 Classification of medical outcomes, with examples from gastroenterology. trials to support labeling claims (summarized in Fig. 3.2), reflecting the growing recognition of the value of these tools [2]. In general, patients wellbeing is increasingly being regarded by the medical community as an important factor in assessing treatment response. For example, assessment of PROs and health-related quality of life is now considered to be a standard part of care for patients with gastroesophageal reflux disease (GERD) [3]. The aim of this chapter is to describe some of the PRO instruments available for GI diseases and to review their value both in clinical trials and every-day practice. What are PRO measures? A PRO measure is a standardized instrument that assesses any aspect of health status or the benefit of therapy directly from the patient s perspective. PRO measures include a defined list of items to which patients respond using standardized response options and with respect to a defined recall period. They can be broadly grouped into generic, disease-specific, and treatment-specific instruments (Fig. 3.3). Generic PROs report overall health and its effect on aspects of everyday life, and can be used in various patient populations. Examples of generic instruments are the Short-Form 36 general health questionnaire (SF-36) [4] and the Psychological General Well-Being index (PGWB) [5]. These measures allow comparisons to be made between diseases but tend to be less sensitive than the more specific instruments to differences within groups of patients with the same condition [6]. In contrast, disease-specific PRO instruments are highly focused on the problems associated with a specific disease and so minimize the amount of noise that could be introduced by irrelevant items. These instruments allow patients to describe their symptoms (symptom scales) or the effect that their symptoms have on their lives. Disease-specific measures include the Reflux Disease Questionnaire (RDQ) [7] and the Gastrointestinal Symptom Rating Scale (GSRS) [8]. They also include disease-specific quality of life instruments, which measure how much a particular disease affects activities such as working, sleeping, and eating; examples include the Quality Of Life in Reflux And Dyspepsia (QOLRAD) questionnaire [9] and the Inflammatory Bowel Disease Questionnaire (IBDQ) [10]. Lastly, PROs can be treatment-specific. For example, a PRO could measure specific effects of a certain class of drug or type of therapy, such as the Functional Assessment of Cancer Therapy Biologic Response Modifier (FACT-BRM) [11]. The value of PROs (Fig. 3.4) Increasing understanding and recognition of diseases Many individuals with GI diseases do not visit their physician about their symptoms. For example, 17
3 CHAPTER 3 Identify concepts and develop conceptual framework Concepts and domains must be relevant to patients. The intended population and research application should be defined. Create instrument Choose items, recall period, response scales, etc. Patients must be involved in item generation and/or evaluation of content. The content validation process must be documented. Item generation should come from multiple sources. Proof of the importance of content to patients should be sought. Cognitive debriefing should be used to revise measures. Assess measurement properties Reliability: measure test retest reliability, internal consistency and inter interviewer reproducibility. Validity: assess content-related validity, ability to measure the concept and predictive validity. Responsiveness: calculate effect size and standard error of the measurement. Interpretability: uncover the clinically relevant difference and responder definition. Modify instrument Where necessary, change the concepts measured, populations studied, research application, instrumentation or method of administration. Figure 3.2 Summary of the US Food and Drug Administration (FDA) guidance on the development and modification of PRO instruments. population-based studies have shown that the majority of individuals with gastroesophageal reflux symptoms do not visit their primary care physician about them [12,13]. This may be because GI symptoms are generally not perceived as serious. Individuals with GI symptoms also often delay visiting their physician until they have another reason to go [14]. Websites, magazines or waiting-room leaflets that include questionnaires about symptoms can alert patients to recognize their true symptom load and its consequences, Generic Short Form-36 general health questionnaire (SF-36) Psychological General Well- Being index (PGWB) Symptoms Reflux Disease Questionnaire (RDQ) Gastrointestinal Symptom Rating Scale (GSRS) Disease-specific Quality of life Quality Of Life in Reflux and Dyspepsia questionnaire (QOLRAD) Treatmentspecific Functional Assessment of Cancer Therapy Biologic Response Modifier (FACT BRM) Figure 3.3 Classification of PRO instruments. 18
4 PATIENT-REPORTED OUTCOMES Patient management Facilitate patient management Indicate need for treatment changes Consider burden of illness Increasing recognition and understanding Websites, magazines, waiting room leaflets Clinical trials Define eligibility criteria Establish treatment goals Evaluate treatment response PRO instruments Diagnosis Symptom-driven Validated treatment algorithm Health economics Ensure right treatment to the right patient Figure 3.4 The value of PROs in clinical practice and clinical trials. thereby encouraging individuals to talk to a physician about GI problems. Leaflets encouraging patients to raise their concerns with a physician have been associated with increased patient satisfaction [15]. PROs can also improve a physician s understanding of the burden that their patients have. There is increasing evidence of a communication gap between patients and physicians in the reporting of symptoms, which has the potential to lead to underestimation of patients symptom burden [16 20]. For GI diseases specifically, data from clinical trials have shown that clinicians tend to underestimate symptom presence and severity and overestimate the benefits of treatment [21,22]. An improved understanding of the effect that GI symptoms can have on quality of life can also help physicians to highlight possible consequences. PROs in clinical trials Increasingly, the importance of taking into account the patient s perspective during drug development is being recognized [23]. In clinical trials, PRO tools can be used to establish the eligibility criteria that should be used, and also the results that can be expected after treatment. PRO tools should be used before other investigations, to uncover baseline levels, and then later, to assess treatment response. Because some treatment effects are known only to the patient, such as relief of pain, PROs can be essential for assessing the effectiveness of treatments in clinical trials. Tools for diagnosis PROs facilitate symptom-driven diagnosis. Symptoms are a good starting point for diagnosis because the presence and severity of symptoms drive individuals to consult [12,24]. For many GI diseases, a spectrum of symptoms exists. In the absence of objective evidence, PROs can help to establish a standardized cutoff point at which the severity and frequency of symptoms are considered to indicate disease. For example, heartburn is one of the primary symptoms of GERD, yet over 50% of the general population experience heartburn at least once a year. Clearly not all of these individuals are suffering from GERD. A PRO tool that assesses the frequency and severity of symptoms would assist physicians in diagnosing GERD in a standardized way. PROs that are not yet validated may also contribute to more accurate diagnosis. For example, the Reflux Disease Questionnaire (RDQ) assesses 19
5 CHAPTER 3 GERD-related symptoms and gives information on the presence and severity of patient-reported symptoms. This questionnaire has been preliminarily validated for this purpose [25]. Facilitating patient management PROs can be used after diagnosis, to assist with the long-term management of patients. If physicians are made more aware of the burden of illness that their patients experience, including the effect that symptoms have on patients everyday lives, they can more readily assess whether a patient will benefit from treatment. PROs can help a physician to understand the effect that GI symptoms have on health-related quality of life in a standardized way, and so identify where there is a need to treat. For example, the GERD Impact Scale (GIS) is a short, patient-completed questionnaire for patients who have been diagnosed with GERD. It can be used for patients with a new diagnosis, to determine the appropriate level of treatment, and also to help physicians identify currently treated patients who would benefit from changes to their treatment [26]. PROs can help physicians make sure that the most effective treatments are offered to the patients who will benefit most from them. In particular, PROs that evaluate health-related quality of life enable physicians to factor in the patient s burden of illness when considering how best to manage their symptoms. PROs may also help to predict response to treatment. For example, a recent study has shown that a high level of anxiety or a low total well-being score at baseline predicts against a positive response to acid suppression therapy [27]. PROs can also predict mortality over and above traditional measures available to physicians, such as history and risk factors [28]. Health economic evaluation Incorporating PROs into health economic analyses ensures that the benefit of a therapy as felt by the patient is quantified and included in economic decisions. PROs can therefore help make sure that, from a health economic perspective, each individual receives the most appropriate treatment. Standardized ratios such as cost per Quality Adjusted Life Year (QALY) allow the cost-effectiveness of different treatments to be compared. QALYs can also be used to compare treatment outcomes for different diseases, while the derived utility values are useful for comparing the burden of illness of various chronic conditions. PROs can help quantify the savings in cost associated with a treatment. For example, self-rated measurement of increased productivity at work can contribute to assessing the indirect costs saved. Construction and validation of PRO instruments The value of a PRO instrument is dependent on the quality of its development, and it is important that patients are involved during this process. Using patient and physician focus groups reduces the risk of measuring irrelevant symptoms. The reliability and validity of each instrument need to be confirmed [29]. In addition, their ability to detect change and interpretability also need to be tested if they are to be used in clinical trials [6]. Limitations of PROs There are some limitations to the usefulness of PROs. Individuals may not answer honestly, especially if diagnosis of a particular disease via a PRO instrument offers access to treatment. As well as the possibility that they may not remember their experiences and so answer incorrectly, they may seek to fulfill a role as a good patient. For example, they may report that their symptoms have improved as they feel that this is an appropriate response after having received treatment or because they feel grateful for the effort that a physician has shown. Conclusions Physicians can often underestimate the presence and severity of symptoms, and so there is a clinical need for standardized patient-reported symptom assessment. PROs capture the patient s perspective directly, and can be measured in a scientific, reliable, and valid manner. PROs are useful both in clinical trials and for symptom-driven diagnosis in clinical practice. They are particularly valuable in diagnosing and assessing GI diseases because many of these diseases have a high symptom burden with little or inaccessible 20
6 PATIENT-REPORTED OUTCOMES objective evidence for disease. PROs have the potential to increase and improve the understanding of the extent of patient suffering as a consequence of GI diseases. Because the wide-ranging effects of GI disorders are not always recognized and well understood by the medical community, PROs have particular importance in this area. In the future, more research is needed on issues such as measuring the cost-effectiveness of GI treatment. Incorporating PROs into cost analysis will help to ensure that when the costs of various treatments are compared, the benefits that patients themselves experience can be taken into account. References 1 Rath HC, et al. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: Impact of level of experience. Gastrointest Endosc 2004;60:44. 2 Food and Drug Administration. Patient-reported outcome measures: Use in medical product development to support labeling claims. Rockville, MD: US Department of Health and Human Services, 2006; (last accessed August 2013). 3 Dent J, et al. on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management the Genval Workshop Report. Gut 1999;44(Suppl. 2):S1. 4WareJE.SF-36 Health Survey: Manual and Interpretation Guide. Boston: New England Medical Centre, Dupuy HJ. The Psychological General Well-being (PGWB) Index. In: Wenger NK et al. (eds), Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing Inc, 1984: Talley NJ, Wiklund I. Patient reported outcomes in reflux disease: an overview of available measures. Qual Life Res 2005;14:21. 7 Veldhuyzen van Zanten S, et al. Validation of the reflux disease questionnaire (RDQ), a new symptom scale for use in patients with upper gastrointestinal symptoms. Gastroenterology 2004;126(Suppl. 2):T Svedlund J, et al. GSRS a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33: Wiklund IK, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998;583: Guyatt G, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96: Bacik J, et al. The functional assessment of cancer therapy-brm (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004;13: Rey E, et al. Medical consultation for gastro-oesophageal reflux symptoms: reasons and associated factors. Digestion 2004;70: Wong WM, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003;18: Niemcryk SJ, et al. Outpatient experience of patients with GERD in the United States: analysis of the National Ambulatory Medical Care Survey. Dig Dis Sci 2005;50: Little P, et al. Randomised controlled trial of effect of leaflets to empower patients in consultations in primary care. Br Med J 2004;328: Corley DA et al. Accuracy of endoscopic databases for assessing patient symptoms: comparison with selfreported questionnaires in patients infected with the human immunodeficiency virus. Gastrointest Endosc 2000;51: Fontaine A, et al. Physicians recognition of the symptoms experienced by HIV patients: how reliable? JPain Symptom Manage 1999;18: Justice AC, et al. Clinical importance of providerreported HIV symptoms compared with patient-report. Med Care 2001;39: Suarez-Almazor ME, et al. Lack of congruence in the ratings of patients health status by patients and their physicians. Med Decis Making 2001;21: Nekolaichuk CL, et al. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 1999;13: Fallone CA, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004;20: McColl E, et al. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians assessments agree with those of their patients? Am J Gastroenterol 2005;100: Acquadro C, et al. Incorporating the patient s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, Value Health 2003;6: Kennedy T, Jones R. The prevalence of gastrooesophageal reflux symptoms in a UK population 21
7 CHAPTER 3 and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14: Shaw MJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96: Jones R, et al. Validation of the Gastroesophageal Reflux Disease Impact Scale a patient management tool for primary care. Gastroenterol 2006;130(4 Suppl 2): M Wiklund I, et al. Psychological factors as a predictor of treatment response in patients with heartburn: A pooled analysis of clinical trials. Scand J Gastroenterol 2006;41: Heistaro S, et al. Self-rated health and mortality: a longterm prospective study in eastern Finland. J Epidemiol Community Health 2001;55: Guyatt GH, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:
Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease
Volume 11 Number 4 2008 VALUE IN HEALTH Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease Ola Junghard, PhD, 1 Ingela Wiklund, PhD
More informationHealth-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia
Aliment Pharmacol Ther 23; 17: 835 84. doi: 1.146/j.269-2813.23.1497.x Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia A. QUADRI & N. VAKIL University of Wisconsin
More informationStudy Endpoint Considerations: Final PRO Guidance and Beyond
Study Endpoint Considerations: Final PRO Guidance and Beyond Laurie Burke Associate Director for Study Endpoints and Labeling OND/CDER/FDA Presented at: FIRST ANNUAL PATIENT REPORTED OUTCOMES (PRO) CONSORTIUM
More informationThe Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 160-164 ORiginal Article The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationQuality of life in patients with gastroesophageal reflux disease in an Iranian population
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Quality of life in patients with gastroesophageal reflux disease
More informationHealth-related quality of life (HRQOL) is widely
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:187 195 Health-Related Quality of Life in Patients Attending a Gastroenterology Outpatient Clinic: Functional Disorders Versus Organic Diseases MAGNUS SIMRÉN,*
More informationUnderstanding gastro-oesophageal reflux disease: a patient-cluster analysis
ORIGINAL PAPER Understanding gastro-oesophageal reflux disease: a patient-cluster analysis A. King, 1 C. MacDonald, 1 C. Örn 2 doi: 10.1111/j.1742-1241.2008.01929.x OnlineOpen: This article is available
More informationFDA s GREAT Workshop. Industry Perspective: Development Activities Towards Phase 3 Endpoints. September 19, 2012
FDA s GREAT Workshop Industry Perspective: Development Activities Towards Phase 3 Endpoints Malcolm Hill, Pharm.D. Meritage Pharma, Inc. San Diego, CA 09/19/12 1 September 19, 2012 Presentation Overview
More informationAccepted Article. Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful? Constanza Ciriza de los Ríos
Accepted Article Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful? Constanza Ciriza de los Ríos DOI: 10.17235/reed.2016.4267/2016 Link: PDF Please cite this article
More informationQuality Of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in Iranian Patients with GERD: A Validation Study
84 Original Article Quality Of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in Iranian Patients with GERD: A Validation Study S Tofangchiha 1, H Razjouyan 2, S Nasseri-Moghaddam 3* 1. 2. 3. Assistant
More informationValidation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia
Aliment Pharmacol Ther 2005; 22: 357 363. doi: 10.1111/j.1365-2036.2005.02572.x Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia B.
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationThe Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis and Non-Erosive Reflux Disease
ARC Journal of Hepatology and Gastroenterology Volume 1, Issue 1, 2016, PP 3-8 www.arcjournals.org The Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis
More informationClinician-reported Outcomes (ClinROs), Concepts and Development
Clinician-reported Outcomes (ClinROs), Concepts and Development William Lenderking, PhD, Senior Research Leader; Dennis Revicki, PhD, Senior Vice President, Outcomes Research In heathcare, there are many
More informationNimish Vakil 1*, Anna Niklasson 2, Hans Denison 2 and Anna Rydén 2
Vakil et al. BMC Gastroenterology 2014, 14:177 RESEARCH ARTICLE Open Access Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal
More informationRelationship between Psychological Factors and Quality of Life in Subtypes of Gastroesophageal Reflux Disease
Gut and Liver, Vol. 3, No. 4, December 2009, pp. 259-265 original article Relationship between Psychological Factors and Quality of Life in Subtypes of Gastroesophageal Reflux Disease Jung-Hwan Oh*, Tae-Suk
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationORIGINAL ARTICLES ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:612 619 ORIGINAL ARTICLES ALIMENTARY TRACT Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux
More informationPatient assessment of treatment satisfaction: methods and practical issues
iv40 Patient assessment of treatment satisfaction: methods and practical issues D A Revicki... Measurement of treatment satisfaction in gastrooesophageal reflux disease (GORD) is compromised by an insufficient
More informationQuality of life assessment in gastro-oesophageal reflux disease
iv35 Quality of life assessment in gastro-oesophageal reflux disease E J Irvine... Gut 2004;53(Suppl IV):iv35 iv39. doi: 10.1136/gut.2003.034314 Health related quality of life (HRQoL) is determined by
More informationEvaluation of a new quality of life questionnaire for patients with irritable bowel syndrome
Aliment Pharmacol Ther 1997; 11: 547±552. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome B. A. HAHN, L. J. KIRCHDOERFER, S. FULLERTON* & E. MAYER* Pharmacoeconomic
More informationWhy use PROs? The relation to clinical outcomes
Introduction to Patient-Reported Outcomes (PROs) March 2-4 2004, Sigtuna, Sweden Why use PROs? The relation to clinical outcomes Olivier CHASSANY, MD, PhD Medical Manager, Clinical Research Dept (institutional
More informationSymptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs
iv1 Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs J Dent, D Armstrong, B Delaney, P Moayyedi, N J Talley, N Vakil... There has
More informationIntroducing the OWLQOL and WRSM Instruments
Introducing the OWLQOL and WRSM Instruments Previously developed weight-specific Patient-Reported-Outcome measures (PROs) were either developed for application to more severely obese populations, or without
More informationINTRODUCTION. Key Words: Gastroesophageal reflux; Agreement; Experience. ORiginal Article
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 154-159 ORiginal Article Endoscopic Experience Improves Interobserver Agreement in the Grading of Esophagitis by Los Angeles Classification: Conventional Endoscopy
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationACID REFLUX & GERD: The Unsettling Reality in Canada
ACID REFLUX & GERD: The Unsettling Reality in Canada gerd fact 1 see page 8 Canadian Society of Intestinal Research On average, ARD patients wait over two years before seeking care 1. 1 gerd fact 2 see
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationPatient Reported Outcomes
Date Patient Reported Outcomes Presented by: Ari Gnanasakthy RTI Health Solutions 9 th Feb 2015 RTI Health Solutions Research Triangle Park, NC, USA Ann Arbor, MI, USA Barcelona, Spain Ljungskile, Sweden
More informationPrevalence of gastrointestinal symptoms in Brunei Darussalam
Gastrointestinal symptoms in Brunei 39 Prevalence of gastrointestinal symptoms in Brunei Darussalam Vui Heng Chong, Gastroenterology Unit, Department of Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS)
More informationVALUE IN HEALTH 19 (2016) Available online at journal homepage:
VALUE IN HEALTH 19 (2016) 829 833 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationThe full complete version includes LDQ-SF Overview information LDQ-SF Scoring/ Administration instructions LDQ-SF Complete Quesionnaire/Assessment
This is a Sample version of the Leeds Dyspepsia Questionnaire- Short Form (LDQ-SF) The full version of Leeds Dyspepsia Questionnaire -Short Form (LDQ-SF) comes without sample watermark. The full complete
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationWHAT IS GASTROESOPHAGEAL REFLUX DISEASE (GERD)?
WHAT IS GASTROESOPHAGEAL REFLUX DISEASE (GERD)? The term gastroesophageal reflux describes the movement (or reflux) of stomach contents back up into the esophagus, the muscular tube that extends from the
More informationPatient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance. Donald L. Patrick University of Washington
Patient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance Paul-Martini-Stiftung Berlin-Brandenburgische Akademie der Wissenschaften 6 March 2008 10:45 11:05 Donald L. Patrick
More informationPATIENT REPORTED OUTCOMES
Introduction to Clinical Research: A Two-week Intensive Course PATIENT REPORTED OUTCOMES Albert W. Wu, MD, MPH Overview 1. Importance of patient perspective 2. Definitions 3. Key concepts to measure as
More informationSetting The setting was primary and secondary care. The economic study was carried out in the UK.
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis Ford A C, Qume M, Moayyedi P, Arents N L, Lassen A T, Logan R F, McColl K E, Myres P,
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationComparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal Diseases
ORIGINAL PAPER Surg. Gastroenterol. Oncol. 2018;23(3):198-203 DOI: 10.21614/sgo-23-3-198 Comparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More informationSunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Rheumatology 2003;42(Suppl. 3):iii32 iii39 doi:10.1093/rheumatology/keg496, available online at www.rheumatology.oupjournals.org Measuring dyspepsia-related health in randomized trials: the Severity of
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationIMPact of GastRo-oEsoPHaGEal REflux DIsEasE on
124 Eu Ro PE an JouR nal of MED I cal RE search March 30, 2010 Eur J Med Res (2010) 15: 124-130 I. Holzapfel Publishers 2010 IMPact of GastRo-oEsoPHaGEal REflux DIsEasE on WoRk PRoDuctIvIty DEsPItE therapy
More informationMISCONCEPTION OF HEART ATTACK PAIN WITH HEART BURN - HOW COMMON IS IT? Sehrish Khan, Rizwan Aziz Memon, Muhammad Farhan Khan, Mudassir Iqbal Dar
Pak Heart J ORIGINAL ARTICLE MISCONCEPTION OF HEART ATTACK PAIN WITH HEART BURN - HOW COMMON IS IT? 1 2 3 4 Sehrish Khan, Rizwan Aziz Memon, Muhammad Farhan Khan, Mudassir Iqbal Dar 1 Dow Medical College,
More informationValidated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population
Aliment Pharmacol Ther 2005; 22: 483 488. doi: 10.1111/j.1365-2036.2005.02621.x Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population A. O. O.
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationThe Kalixanda Study. Upper GI pathology in the general population
The Kalixanda Study Upper GI pathology in the general population The Kalixanda Study The project group Lars Agréus, PhD, GP, project leader Pertti Aro, GP Jukka Ronkainen, GP Tom Storskrubb, gastroenterologist
More information190 Index Case studies, abdominal pain, 2 Crohn s disease, 2 3, cyclic vomiting syndrome (CVS), 2 fecal incontinence (FI), 2 medical c
Index Abdominal pain, case study, 2 Achalasia, 75 Acupuncture 108 American Academy of Pediatrics, 49 Anxiety, 8 9, 98 Autism, GI disorders and, 25 27 BASC. See Behavior Assessment System for Children (BASC)
More informationAssessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments
Assessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments C. Chrea, E. Spies, E. Afolalu, N. Mainy, S. Gallot, P. Binggeli, E. Clerc, R. Weitkunat PMI
More informationDiscontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial
Alimentary Pharmacology & Therapeutics Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial E. BJÖRNSSON, H. ABRAHAMSSON, M. SIMRÉN, N. MATTSSON,
More informationValidation of a specific quality of life questionnaire for functional digestive disorders
Gut 1999;44:527 533 527 Service de Médecine, Hôpital Lariboisière, 75010 Paris, France O Chassany J F Bergmann C Caulin MAPI Values, 27 rue de la Villette, 69003 Lyon, France P Marquis Institut de Recherche
More informationFunctional Heartburn and Dyspepsia
Functional Heartburn and Dyspepsia Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Objectives Understand the means of diagnosing functional heartburn
More informationManagement of reflux disease
iv67 DYSPEPSIA MANAGEMENT Management of reflux disease J Dent... The management of reflux disease can be divided into three major phases, the first being diagnosis and severity assessment, the second,
More informationPatient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life
Patient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life David Victorson, Ph.D. Assistant Professor Department of Medical Social Sciences Northwestern University Feinberg
More informationTypically characterized by frequent or troublesome heartburn REVIEW
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:816 822 REVIEW What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment? PETER BYTZER Department of Medical Gastroenterology,
More informationREVIEW ARTICLE: ENDPOINTS USED IN FUNCTIONAL DYSPEPSIA DRUG THERAPY TRIALS
REVIEW ARTICLE: ENDPOINTS USED IN FUNCTIONAL DYSPEPSIA DRUG THERAPY TRIALS Daphne Ang, Nicholas J Talley, Magnus Simrén, Pieter Janssen, Guy E Boeckxstaens, Jan Tack To cite this version: Daphne Ang, Nicholas
More informationGuidance for the improved integration of Health-Related Quality of Life assessment in the drug regulatory process
Guidance for the improved integration of Health-Related Quality of Life assessment in the drug regulatory process The ERIQA* Working Group experience * European Regulatory Issues on Quality of life Assessment
More informationPatient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know?
Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Peter D.R. Higgins Director, IBD Program University of Michigan What are PROs? ClinRO Patient- Reported
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationCigarette Smoking and its Association with Overlapping Gastroesophageal Reflux Disease, Functional Dyspepsia, or Irritable Bowel Syndrome
ORIGINAL ARTICLE Cigarette Smoking and its Association with Overlapping Gastroesophageal Reflux Disease, Functional Dyspepsia, or Irritable Bowel Syndrome Yasuhiro Fujiwara, Makiko Kubo, Yukie Kohata,
More informationAge and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study
Gut 2001;49:29 34 29 Digestive Disease Center, Medical University of South Carolina, USA M B Wallace V L Durkalski J Vaughan Y Y Palesch P B Cotton University of Kentucky N J Nickl Wilford Hall United
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding 1.1 Short title Acute upper GI bleeding
More informationRole of Endoscopy in Gastroesophageal Reflux Disease
Role of Endoscopy in Gastroesophageal Reflux Disease Joachim Mössner University of Leipzig Berlin, May 4, 2006 Role of Endoscopy in Gastroesophageal Reflux Disease In Diagnosis Magnifying endoscopy Chromoendoscopy
More informationStudy population The study population comprised a hypothetical cohort of patients with confirmed reflux oesophagitis.
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical
More informationOveruse of acid suppressant drugs in patients with chronic renal failure
Nephrol Dial Transplant (2003) 18: 570 575 Original Article Overuse of acid suppressant drugs in patients with chronic renal failure Hans Strid, Magnus Simrén and Einar S. Björnsson Department of Internal
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European
More informationRE: Proposed Decision Memo for Screening for Hepatitis C Virus (HCV) in Adults (CAG-00436N)
April 2, 2014 Tamara Syrek Jensen, JD Acting Director Coverage and Analysis Group Center for Clinical Standards and Quality Centers for Medicare and Medicaid Services U.S. Department of Health and Human
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Faculty representative: David L. Burns, MD, CNSP Resident representative: Tom Castiglione, MD Revision date: March 6, 2006
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471
Eluxadoline for treating irritable bowel syndrome with diarrhoea Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 NICE 2017. All rights reserved. Subject to Notice of
More informationGastroesophageal reflux disease prevalence among school teachers of Saudi Arabia and its impact on their daily life activities
Original Article Gastroesophageal reflux disease prevalence among school teachers of Saudi Arabia and its impact on their daily life activities Abdulrahman Mohammed Altwigry 1, Majed Saud Almutairi 1,
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationΑναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας
Αναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας Σύγκρουση συμφερόντων Γιώργος Μπάμιας τιμητικές αμοιβές απο
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationEvaluation of validity of Edinburgh Dysphagia score in predicting oesophageal cancer in patients with dysphagia
Quest Journals Journal of Medical and Dental Science Research Volume 2~ Issue 12 (2015) pp: 09-13 ISSN(Online) : 2394-076X ISSN (Print):2394-0751 www.questjournals.org Research Paper Evaluation of validity
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationApproaches to uninvestigated dyspepsia
iv42 DYSPEPSIA MANAGEMENT Approaches to uninvestigated dyspepsia R H Jones... Uninvestigated dyspepsia refers to patients with new or recurrent dyspeptic symptoms in whom no investigations have previously
More informationSetting The setting was primary care. The economic analysis was conducted in Glasgow, UK.
Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting Forrest E H, MacKenzie J F, Stuart R C, Morris A J Record Status This is a critical abstract
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
Appendix B: Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE Post publication note: The title of this guideline changed during development. This scope was published before the guideline
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationReproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux
3 Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux A.J. Bredenoord B.L.A.M. Weusten R. Timmer A.J.P.M. Smout Dept. of Gastroenterology, St. Antonius
More informationEndoscopic vs Surgical Therapies for GERD: Is it Time to Put down the Scalpel?
Endoscopic vs Surgical Therapies for GERD: Is it Time to Put down the Scalpel? Brian R. Smith, MD, FACS, FASMBS Associate Professor of Surgery & General Surgery Residency Program Director UC Irvine Medical
More informationAssessment of reflux symptom severity: methodological options and their attributes
iv28 Assessment of reflux symptom severity: methodological options and their attributes P Bytzer... Despite major advances in our understanding of reflux disease, the management of this disorder still
More informationSetting The setting was primary care. The economic study was carried out in the Netherlands.
Economic evaluation of a randomized trial comparing Helicobacter pylori test-and treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting Klok R M, Arents N L, de Vries R,
More informationNational Institute for Health and Clinical Excellence. Health Technology Appraisal. Prucalopride for the treatment of chronic constipation in women
Health Technology Appraisal Summary form Prucalopride for the treatment of chronic constipation in women Comment 1: the draft remit Appropriateness Movetis Movetis entirely welcomes the opportunity to
More informationEducational Program on Patient-Reported Outcomes (PROs) in Clinical Trials
SEMINAR May 23, 2003 09:00-16:45 pm INAMI, 211 Tervueren Av, BRUSSELS Educational Program on Patient-Reported Outcomes (PROs) in Clinical Trials Facilitators Catherine Acquadro, Olivier Chassany Introductions
More informationSymptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 165-169 ORiginal Article Symptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease Chul-Hyun Lim, Myung-Gyu
More informationIs Physical Activity Effective In Reducing The Gastrointestinal Symptoms Associated with Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is Physical Activity Effective In Reducing
More informationClinical and endoscopic features of Chinese reflux esophagitis patients
Online Submissions: wjg.wjgnet.com World J Gastroenterol 28 March 28; 14(12): 1866-1871 World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com 28 WJG. All rights reserved. CLINICAL RESEARCH Clinical
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationDevelopment of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)
954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationInterventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540
Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease Interventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540 Your
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More informationUpper Gastrointestinal Research (UGIR) Jesper Lagergren, professor of surgery Karolinska Institutet and King s Health Partners London
Upper Gastrointestinal Research (UGIR) Jesper Lagergren, professor of surgery Karolinska Institutet and King s Health Partners London UGIR SIMSAM funding in 2008 Creation of UGIR (Upper Gastro-Intestinal
More informationSystematic Review on Epidemiology of Gastroesophageal Reflux Disease in Asia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:398 407 REVIEWS Systematic Review on Epidemiology of Gastroesophageal Reflux Disease in Asia BENJAMIN C. Y. WONG* and YOSHIKAZU KINOSHITA *Department of
More information